Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Associations between baseline biomarkers and lung function in HIV-positive individuals.

MacDonald DM, Zanotto AD, Collins G, Baker JV, Czarnecki M, Loiza E, Nixon DE, Papastamopoulos V, Wendt CH, Wood R, Kunisaki KM; INSIGHT START Pulmonary Substudy Group.

AIDS. 2019 Mar 15;33(4):655-664. doi: 10.1097/QAD.0000000000002101.

PMID:
30601153
2.

A Guinea pig cytomegalovirus resistant to the DNA maturation inhibitor BDCRB.

Ourahmane A, Sauer A, Nixon DE, Murphy C, Mondello M, Douglass Chiu E, Siegmund S, Wang JB, McVoy MA.

Antiviral Res. 2018 Jun;154:44-50. doi: 10.1016/j.antiviral.2018.04.006. Epub 2018 Apr 9.

3.

Sequence homology between HLA-bound cytomegalovirus and human peptides: A potential trigger for alloreactivity.

Hall CE, Koparde VN, Jameson-Lee M, Elnasseh AG, Scalora AF, Kobulnicky DJ, Serrano MG, Roberts CH, Buck GA, Neale MC, Nixon DE, Toor AA.

PLoS One. 2017 Aug 11;12(8):e0178763. doi: 10.1371/journal.pone.0178763. eCollection 2017.

4.

Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).

Nixon DE, Bosch RJ, Chan ES, Funderburg NT, Hodder S, Lake JE, Lederman MM, Klingman KL, Aberg JA; AIDS Clinical Trials Group Study A5275 Team.

J Clin Lipidol. 2017 Jan - Feb;11(1):61-69. doi: 10.1016/j.jacl.2016.09.017. Epub 2016 Oct 5.

5.

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, Clarke A, Corbelli GM, Ekong E, Emery S, Finley EB, Florence E, Infante RM, Kityo CM, Madero JS, Nixon DE, Tedaldi E, Vestbo J, Wood R, Connett JE; INSIGHT START Pulmonary Substudy Group.

Lancet Respir Med. 2016 Dec;4(12):980-989. doi: 10.1016/S2213-2600(16)30319-8. Epub 2016 Oct 20.

6.

A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Adler SP, Manganello AM, Lee R, McVoy MA, Nixon DE, Plotkin S, Mocarski E, Cox JH, Fast PE, Nesterenko PA, Murray SE, Hill AB, Kemble G.

J Infect Dis. 2016 Nov 1;214(9):1341-1348. Epub 2016 Aug 11.

7.

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.

Bajaj JS, Sterling RK, Betrapally NS, Nixon DE, Fuchs M, Daita K, Heuman DM, Sikaroodi M, Hylemon PB, White MB, Ganapathy D, Gillevet PM.

Aliment Pharmacol Ther. 2016 Sep;44(6):638-43. doi: 10.1111/apt.13732. Epub 2016 Jul 15.

8.

Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Kunisaki KM, Niewoehner DE, Collins G, Nixon DE, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett JE; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:119-28. doi: 10.1111/hiv.12240.

9.

HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.

Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, Badley AD, Nixon DE, Lundgren JD, Tracy RP, Neaton JD; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):128-34. doi: 10.1097/QAI.0b013e318252f99f.

10.

Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC; INSIGHT SMART Study Group.

J Infect Dis. 2011 Mar 15;203(6):780-90. doi: 10.1093/infdis/jiq118. Epub 2011 Jan 20.

11.

Biomarkers of immune dysfunction in HIV.

Nixon DE, Landay AL.

Curr Opin HIV AIDS. 2010 Nov;5(6):498-503. doi: 10.1097/COH.0b013e32833ed6f4. Review.

12.

Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.

Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):36-43. doi: 10.1097/QAI.0b013e3181f7f61a.

13.

Determination of the underlying cause of death in three multicenter international HIV clinical trials.

Lifson AR; INSIGHT Cause of Death Writing Group, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.

HIV Clin Trials. 2008 May-Jun;9(3):177-85. doi: 10.1310/hct0903-177.

14.

Review of tenofovir-emtricitabine.

Masho SW, Wang CL, Nixon DE.

Ther Clin Risk Manag. 2007 Dec;3(6):1097-104.

15.
16.

When to start antiretroviral therapy.

Wang C, Masho SW, Nixon DE.

Curr HIV/AIDS Rep. 2006 Jul;3(2):66-73. Review.

PMID:
16608662
20.

Zinc increases the activity of vitamin D-dependent promoters in osteoblasts.

Lutz W, Burritt MF, Nixon DE, Kao PC, Kumar R.

Biochem Biophys Res Commun. 2000 Apr 29;271(1):1-7.

PMID:
10777672
23.

Circularization and cleavage of guinea pig cytomegalovirus genomes.

McVoy MA, Nixon DE, Adler SP.

J Virol. 1997 Jun;71(6):4209-17.

24.

Determination of silicon in breast and capsular tissue from patients with breast implants performed by inductively coupled plasma emission spectroscopy. Comparison with tissue histology.

McConnell JP, Moyer TP, Nixon DE, Schnur PL, Salomao DR, Crotty TB, Weinzweig J, Harris JB, Petty PM.

Am J Clin Pathol. 1997 Feb;107(2):236-46.

PMID:
9024074
25.
27.
28.
29.

Blood-collection device for trace and ultra-trace metal specimens evaluated.

Moyer TP, Mussmann GV, Nixon DE.

Clin Chem. 1991 May;37(5):709-14.

30.

Oxalate, silicon and vanadium in acquired cystic kidney disease.

Marco-Franco JE, Torres VE, Nixon DE, Wilson DM, James EM, Bergstralh EJ, McCarthy JT.

Clin Nephrol. 1991 Feb;35(2):52-8.

PMID:
2019015
32.

Transfusional iron overload in patients undergoing dialysis: treatment with erythropoietin and phlebotomy.

McCarthy JT, Johnson WJ, Nixon DE, Jenson BM, Moyer TP.

J Lab Clin Med. 1989 Aug;114(2):193-9.

PMID:
2754306
33.

Comparison of Jarrell-Ash, Perkin-Elmer, and modified Perkin-Elmer nebulizers for inductively coupled plasma analysis.

Nixon DE, Smith GA.

Anal Chem. 1986 Nov;58(13):2886-8. No abstract available.

PMID:
3813022
34.

Routine measurement of calcium, magnesium, copper, zinc, and iron in urine and serum by inductively coupled plasma emission spectroscopy.

Nixon DE, Moyer TP, Johnson P, McCall JT, Ness AB, Fjerstad WH, Wehde MB.

Clin Chem. 1986 Sep;32(9):1660-5.

Supplemental Content

Loading ...
Support Center